Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919212 | 0.82 | L3MBTL1 (0.41) | BCHEL3MBTL1 | |
| SCHEMBL27745025 | 0.81 | GPR119 (0.39) | NR1H2GPR119L3MBTL1 | |
| SCHEMBL27766001 | 0.81 | GPR119 (0.39) | NR1H2GPR119L3MBTL1 | |
| SCHEMBL27745027 | 0.80 | HDAC1 (0.35) | NR1H2GPR119 | |
| SCHEMBL27685900 | 0.80 | MEN1 (0.44) | L3MBTL1 | |
| SCHEMBL475285 | 0.80 | NPC1 (0.41) | NR1H2NR1H3GPR119L3MBTL1 | |
| SCHEMBL28993218 | 0.80 | KDM4E (0.38) | NR1H2NR1H3GPR119 | |
| SCHEMBL27666917 | 0.80 | MEN1 (0.44) | L3MBTL1 | |
| SCHEMBL4919206 | 0.79 | TSHR (0.44) | BCHEL3MBTL1 | |
| SCHEMBL3339817 | 0.79 | ALDH1A1 (0.42) | NR1H2GPR119L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114276411-B | Solid phase synthesis method of cyclic peptide compound containing trithioether bond | 北京大学深圳研究生院 | 2024-02-09 | — | — | CN | claimed |
| CN-109748841-B | Method for catalyzing asymmetric synthesis of chiral beta-aminoketone derivative | 浙江工业大学 | 2021-06-01 | — | — | CN | claimed |
| US-8865655-B2 | Depsipeptides and their therapeutic use | KARUS THERAPEUTICS LIMITED (GB) | 2014-10-21 | — | — | US | claimed |
| EP-2089416-B1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | UNIV SOUTHAMPTON (GB) | 2014-02-26 | — | — | EP | claimed |
| EP-2427447-A2 | SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | Pike Pharma GmbH (CH) | 2012-03-14 | — | — | EP | claimed |
| WO-2010128163-A2 | SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20100056434-A1 | Depsipeptides and Their Therapeutic Use | UNIVERSITY OF SOUTHAMPTON (GB) | 2010-03-04 | — | — | US | claimed |
| US-20100056435-A1 | Depsipeptides and Their Therapeutic Use | KARUS THERAPEUTICS LIMITED (GB) | 2010-03-04 | — | — | US | claimed |
| EP-2089415-A1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | Karus Therapeutics Limited (GB) | 2009-08-19 | — | — | EP | claimed |
| EP-2089416-A1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | UNIVERSITY OF SOUTHAMPTON (GB) | 2009-08-19 | — | — | EP | claimed |
| WO-2008062201-A1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | KARUS THERAPEUTICS LIMITED (GB) | 2008-05-29 | — | — | WO | claimed |
| WO-2008062232-A1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | UNIVERSITY OF SOUTHAMPTON (GB) | 2008-05-29 | — | — | WO | claimed |
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | NI LIMING | 2006-08-24 | — | — | US | claimed |
| JP-2005516941-A | — | — | 2005-06-09 | — | — | JP | claimed |
| EP-1465854-A4 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS INC (US) | 2005-06-08 | — | — | EP | claimed |
| EP-1465854-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | Atherogenics, Inc. (US) | 2004-10-13 | — | — | EP | claimed |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2004-03-11 | — | — | US | claimed |
| WO-2003053368-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2003-07-03 | — | — | WO | claimed |
| CN-114276411-B | Solid phase synthesis method of cyclic peptide compound containing trithioether bond | 北京大学深圳研究生院 | 2024-02-09 | — | — | CN | disclosed |
| US-5859007-A | TREATMENT OF DIABETES, OBESITY | GLAXO WELLCOME INC. (US) | 1999-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, HSD17B7, CYP11B2 | NR1H2 83/4885CHRM2 3773/4885CHRM4 4283/4885 |
| US-20100056435-A1 | Depsipeptides and Their Therapeutic Use | HDAC3, HDAC6, HDAC7 | NR1H2 1021/4885CHRM2 718/4885CHRM4 956/4885 |
| US-20100056434-A1 | Depsipeptides and Their Therapeutic Use | HDAC11, HDAC1, HDAC6 | NR1H2 597/4885CHRM2 3804/4885CHRM4 4263/4885 |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, CYP11B1, HSD17B7 | NR1H2 94/4885CHRM2 3357/4885CHRM4 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.